369 related articles for article (PubMed ID: 9733483)
1. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
2. Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation.
Desbène S; Van HD; Michel S; Koch M; Tillequin F; Fournier G; Farjaudon N; Monneret C
Anticancer Drug Des; 1998 Dec; 13(8):955-68. PubMed ID: 10335269
[TBL] [Abstract][Full Text] [Related]
3. Intensely cytotoxic anthracycline prodrugs: glucuronides.
Bakina E; Wu Z; Rosenblum M; Farquhar D
J Med Chem; 1997 Dec; 40(25):4013-8. PubMed ID: 9406592
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
5. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
[TBL] [Abstract][Full Text] [Related]
6. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
8. Cell surface display of a lysosomal enzyme for extracellular gene-directed enzyme prodrug therapy.
Heine D; Müller R; Brüsselbach S
Gene Ther; 2001 Jul; 8(13):1005-10. PubMed ID: 11438835
[TBL] [Abstract][Full Text] [Related]
9. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.
Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P
Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042
[TBL] [Abstract][Full Text] [Related]
10. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
11. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy.
Sinha SC; Li LS; Watanabe S; Kaltgrad E; Tanaka F; Rader C; Lerner RA; Barbas CF
Chemistry; 2004 Oct; 10(21):5467-72. PubMed ID: 15378729
[TBL] [Abstract][Full Text] [Related]
12. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for sarcoma utilizing adenoviral transfer of the beta-glucuronidase and bax genes and an anthracyline prodrug.
Miller SD; Mohiuddin I; Cao XX; Ozvaran MK; Daniel JC; Roy Smythe W
J Surg Res; 2004 Oct; 121(2):153-8. PubMed ID: 15501454
[TBL] [Abstract][Full Text] [Related]
16. Self-immolative anthracycline prodrugs for suicide gene therapy.
Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
[TBL] [Abstract][Full Text] [Related]
17. A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs.
Papot S; Combaud D; Gesson JP
Bioorg Med Chem Lett; 1998 Sep; 8(18):2545-8. PubMed ID: 9873577
[TBL] [Abstract][Full Text] [Related]
18. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
19. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates.
Gesson JP; Jacquesy JC; Mondon M; Petit P; Renoux B; Andrianomenjanahary S; Dufat-Trinh Van H; Koch M; Michel S; Tillequin F
Anticancer Drug Des; 1994 Oct; 9(5):409-23. PubMed ID: 7945725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
